Literature DB >> 9337306

Malignant effusive disease of the pleura and pericardium.

M M DeCamp1, S J Mentzer, S J Swanson, D J Sugarbaker.   

Abstract

Malignant pleural and pericardial effusions are a common problem in the treatment of patients with lung cancer, breast cancer, or lymphoma and may occur with any malignancy. These effusions are frequently symptomatic and, in the case of the pleural space, may be the presenting sign of cancer. In other patients, they represent markers of recurrent, disseminated, or advanced disease. Given the poor prognosis of most patients presenting with these effusions, reducing symptoms and improving quality of life are the primary goals of treatment. Permanent drainage and/or obliteration of the pleural or pericardial space are crucial to the effective management of the effusion and will provide long-term palliation. Immediate relief can be accomplished via external drainage, but definitive therapy may often also require interventional radiology, cardiology, and thoracic surgery, as well as medical and radiation oncology. The pathophysiology, diagnosis, and treatment of malignant pleural and pericardial effusions are discussed in this article.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9337306     DOI: 10.1378/chest.112.4_supplement.291s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  14 in total

Review 1.  Neoplastic pericardial effusion.

Authors:  Marwan M Refaat; William E Katz
Journal:  Clin Cardiol       Date:  2011-09-16       Impact factor: 2.882

2.  Cardiac tamponade: a rare presentation from a rare metastatic site in oral squamous cell carcinoma.

Authors:  Yao-Te Tsai; Shih-Wei Kuo; Sheng-Po Hao
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-19       Impact factor: 2.503

3.  Caring for a patient with malignant pleural effusion.

Authors:  Jeanne Held-Warmkessel; Linda Schiech
Journal:  Nursing       Date:  2008-11

4.  Pleural fluid analysis of lung cancer vs benign inflammatory disease patients.

Authors:  R Kremer; L A Best; D Savulescu; M Gavish; R M Nagler
Journal:  Br J Cancer       Date:  2010-03-09       Impact factor: 7.640

5.  Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.

Authors:  Witold Zbyszek Tomkowski; Joanna Wiśniewska; Monika Szturmowicz; Paweł Kuca; Janusz Burakowski; Jarosław Kober; Anna Fijałkowska
Journal:  Support Care Cancer       Date:  2003-09-23       Impact factor: 3.603

6.  Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.

Authors:  Ianko D Iankov; Pavlos Msaouel; Cory Allen; Mark J Federspiel; Peggy A Bulur; Allan B Dietz; Dennis Gastineau; Yasuhiro Ikeda; James N Ingle; Stephen J Russell; Evanthia Galanis
Journal:  Breast Cancer Res Treat       Date:  2009-11-06       Impact factor: 4.872

7.  Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusion in patients with malignancies?

Authors:  Jefferson Luiz Gross; Tatiana Guilherme Disanzio; Riad Naim Younes; Fabio José Haddad; Rodrigo Afonso da Silva; Antonio Bomfim Marçal Avertano
Journal:  World J Surg       Date:  2009-02       Impact factor: 3.352

Review 8.  Management of Malignant Lung Entrapment, the Oncothorax.

Authors:  Roman Petrov; Charles Bakhos; Abbas E Abbas
Journal:  Thorac Surg Clin       Date:  2018-02       Impact factor: 1.750

9.  An aggressive form of non-Hodgkin's lymphoma with pleural and abdominal chylous effusions: A case report and review of the literature.

Authors:  Yajian Jiang; Wanzhuo Xie; Keyue Hu; Jie Sun; Xiaoli Zhu; He Huang
Journal:  Oncol Lett       Date:  2013-07-29       Impact factor: 2.967

10.  Malignant Cardiac Tamponade from Non-Small Cell Lung Cancer: Case Series from the Era of Molecular Targeted Therapy.

Authors:  Bob T Li; Antonia Pearson; Nick Pavlakis; David Bell; Adrian Lee; David Chan; Michael Harden; Manu Mathur; David Marshman; Peter Brady; Stephen Clarke
Journal:  J Clin Med       Date:  2014-12-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.